Hutson, Thomas E <br/><br/>
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.  [electronic resource] 

 -  The oncologist  2011 
 - 14-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2011-S2-14  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Benzenesulfonates--therapeutic use<br/>Bevacizumab<br/>Carcinoma, Renal Cell--drug therapy<br/>Clinical Trials as Topic<br/>Combined Modality Therapy<br/>Disease-Free Survival<br/>Everolimus<br/>Humans<br/>Immunotherapy--methods<br/>Indoles--therapeutic use<br/>Interferon-alpha--therapeutic use<br/>Interleukin-2--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Molecular Targeted Therapy--methods<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Pyridines--therapeutic use<br/>Pyrroles--therapeutic use<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sunitinib<br/>Treatment Outcome